Flagship bankrolls quest to create gene therapy 2.0, with new viral delivery tech in hand

Count Flagship Pioneering in for the long and convoluted chase of new delivery vehicles that promise to expand the booming gene therapy field. Ring Therapeutics, its latest biotech creation, has a $50 million commitment to explore anellovectors — a whole new class of viral shells that it claims offers the

Read the full article here

Related Articles